Precipio Inc (PRPO)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$27.40+4.90%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · PRPO
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on growing revenue and reaching Adjusted EBITDA profitability as a key financial milestone.
Stated as a priority in 3 recent disclosures. Revenue grew from $18.5M in 2024 to $24.0M in 2025 (30% increase), with quarterly revenue surpassing $7M for the first time in 2026-Q2. Adjusted EBITDA guidance for 2025 is $1.23M. Management's statements and financials show delivering growth and approaching profitability.
“The team continues to make solid progress in adding customers, expanding our pipeline, and growing the business.”
“Precipio's revenues increased from $18.5M in 2024 to $24.0M in 2025, an increase of 30% year over year.”
“Precipio will report Adjusted EBITDA of $1.23M for the full year 2025.”
Focus on improving operating income and reducing net losses to strengthen financial health.
Stated in 3 recent quarters. Operating income improved from negative $859K in 2025-Q1 to positive $542K in 2025-Q4 but declined to negative $1.43M in 2026-Q1. Net income showed similar fluctuations. The trajectory shows limited progress with volatility in profitability.
“Operating income was negative $1.43M and net income negative $1.44M, showing ongoing efforts to improve.”
“Operating income was positive $542K and net income positive $526K, reflecting prior improvement.”
“Operating income was negative $61K and net income negative $79K, indicating fluctuations in profitability.”
Sustain positive cash flow from operating activities to support ongoing operations and growth.
Stated in 4 recent quarters. Cash from operating activities remained positive, ranging from $10K in 2025-Q3 to $366K in 2025-Q4 and $64K in 2026-Q1. Management is maintaining positive cash flow, showing delivering on this priority.
“Cash from operating activities was $64K, reflecting ongoing positive cash flow.”
“Cash from operating activities was $366K, showing strong cash generation.”
“Cash from operating activities was $10K, positive but limited.”
“Cash from operating activities was $353K, supporting operations.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Over the trailing year it converted 0.15x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
4 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.